BioAge Labs Doses First Patient in Phase 2 QUELL-DME Trial for Oral BGE-102

Key highlights

• First participant dosed in the QUELL-DME Phase 2 trial for BGE-102
• Trial targets enrollment of 180 participants across three randomized arms
• BGE-102 is a once-daily oral NLRP3 inhibitor designed to treat retinal disease
• Topline results from the 12-week study are anticipated in the second half of 2027
• Data will inform potential development for other conditions like geographic atrophy

What Happened

BioAge Labs announced the commencement of patient dosing in its QUELL-DME Phase 2 clinical trial. This study evaluates BGE-102, a small-molecule NLRP3 inhibitor administered once daily as an oral tablet. The randomized, controlled trial plans to enroll approximately 180 adults diagnosed with diabetic macular edema. Participants are divided into three groups: one receiving standard anti-VEGF injections with an oral placebo, another receiving anti-VEGF combined with 90 mg of BGE-102, and a third receiving BGE-102 as a monotherapy alongside sham injections. The primary objective is to measure the change in best-corrected visual acuity after 12 weeks of treatment.

Significance

This trial marks a transition for BGE-102 into Phase 2 ocular applications, addressing a market currently dominated by invasive intravitreal injections. By targeting the NLRP3 inflammasome, BioAge aims to mitigate the chronic inflammation that drives fluid accumulation and vision loss in diabetic patients. Management indicated that data from this trial, expected in the second half of 2027, will determine the drug's utility in broader retinal conditions such as geographic atrophy. Successful demonstration of efficacy as either a monotherapy or an adjunct to current standard-of-care could provide a non-invasive alternative for a significant portion of the diabetic population.

Business Overview

BioAge Labs operates as a clinical-stage biotechnology company leveraging a proprietary platform to identify drug targets based on human aging biology. The company’s portfolio focuses on metabolic and inflammatory diseases with high unmet needs. Beyond BGE-102, the company is advancing azelaprag, an oral apelin receptor agonist currently in Phase 2 trials for obesity in combination with incretin mimetics. The company’s methodology involves analyzing longitudinal human data to discover pathways that regulate healthspan. BioAge maintains its primary headquarters in Emeryville, California, and trades on the NASDAQ Global Select Market.

Financial Context

The company currently carries a market capitalization of approximately $303.4 million, following a period of significant volatility. Market data indicates the stock has experienced a 73.03% decline over the last quarter, bringing its Relative Strength Index to 25.2, which is generally considered to be in oversold territory. Annual revenue stands at approximately $9 million, reflecting its status as a development-stage pharmaceutical entity without a commercialized product. Trading volume remains moderate, with a quarterly average of 852,304 shares, as the company maintains its focus on clinical progression and upcoming data readouts across its pipeline.

Down 15.7% since our story on 2 Oct: $6.61 when we broke it → $5.57 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$8.48
15 Sep	$8.18
16 Sep	$7.75
17 Sep	$8.09
18 Sep	$8.06
21 Sep	$8.09
22 Sep	$8.46
23 Sep	$7.89
24 Sep	$7.21
25 Sep	$7.05
28 Sep	$7.18
29 Sep	$7.14
30 Sep	$7.09
1 Oct	$6.81
2 Oct	$6.61
5 Oct	$6.36
6 Oct	$6.29
7 Oct	$6.26
8 Oct	$6.21
9 Oct	$6.34
12 Oct	$5.94
13 Oct	$5.57

BioAge Labs, Inc. · financial snapshot

Share price	$6.61
Market cap	$303M
Revenue (annual)	$9M
1-month price change	-30.57%
Sector	HealthcareDrug Manufacturers - Specialty & Generic

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.